Genentech: Home

News & Features

		2007 Sustainability Report Now Available The 2007 Sustainability Report provides a summary of Genentech's environmental sustainability and employee health, safety and wellness performance for 2007 as well as the company's commitments for 2008.



		Accelerated Approval for Avastin in Breast Cancer On February 22, 2008, the FDA granted accelerated approval for Avastin in combination with paclitaxel chemotherapy for the first-line treatment of advanced HER2-negative breast cancer.


Investor Webcasts >>
Event:	Q2 2008 Financial Results Webcast
Date:	Jul 14, 2008
Time:	1:45 p.m. PT
	See Press Announcement
	Access Slides (1.3MB/PDF)



SCIENTIFIC LEADERSHIP >> Genentech's scientists are some of the most prolific in the industry and in their fields.

Genentech is committed to making sure price is not a barrier to access for patients.

FORTUNE magazine has named Genentech to its "100 Best Companies to Work For" and "America's Most Admired" lists.

Genentech's postdoctoral program offers the chance to do cutting-edge research in an inspiring environment.